| Drug General Information |
| Drug ID |
D06EMM
|
| Former ID |
DIB010260
|
| Drug Name |
CERC-301
|
| Indication |
Major depressive disorder [ICD9: 296.2, 296.3, 710.0; ICD10:F32, F33, M32]
|
Phase 2 |
[1]
|
|---|
| Company |
Cerecor
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Glutamate [NMDA] receptor subunit epsilon 2 |
Target Info |
Antagonist |
[2]
|
|---|
|
KEGG Pathway
|
Ras signaling pathway
|
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Circadian entrainment
|
|
Long-term potentiation
|
|
Glutamatergic synapse
|
|
Dopaminergic synapse
|
|
Alzheimer's disease
|
|
Amyotrophic lateral sclerosis (ALS)
|
|
Huntington's disease
|
|
Cocaine addiction
|
|
Amphetamine addiction
|
|
Nicotine addiction
|
|
Alcoholism
|
|
Systemic lupus erythematosus
|
|
PANTHER Pathway
|
Huntington disease
|
|
Ionotropic glutamate receptor pathway
|
|
Metabotropic glutamate receptor group III pathway
|
|
Metabotropic glutamate receptor group I pathway
|
|
Muscarinic acetylcholine receptor 1 and 3 signaling pathway
|
|
Pathway Interaction Database
|
ErbB4 signaling events
|
|
Reelin signaling pathway
|
|
Reactome
|
EPHB-mediated forward signaling
|
|
Unblocking of NMDA receptor, glutamate binding and activation
|
|
CREB phosphorylation through the activation of CaMKII
|
|
Ras activation uopn Ca2+ infux through NMDA receptor
|
|
RAF/MAP kinase cascade
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
|
|
BDNF signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02459236) A Study of Intermittent Doses of CERC-301 in MDD. |
|---|
| REF 2 | Inhibition of in vivo [3H]MK-801 binding by NMDA receptor open channel blockers and GluN2B antagonists in rats and mice. Eur J Pharmacol. 2015 Aug 29. pii: S0014-2999(15)30217-X. |
|---|
